Publications by authors named "Anna Kryzhanivska"
Purpose: The phase II, multiarm, signal-searching BALTIC study (NCT02937818) assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC).
Patients And Methods: Patients with ES-SCLC with progressive disease during or within 90 days of completing first-line platinum-based chemotherapy received one of three regimens: durvalumab plus tremelimumab followed by durvalumab monotherapy (arm A), adavosertib plus carboplatin (arm B), or ceralasertib plus olaparib (arm C). The primary endpoint was the objective response rate.
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
Gynecol Oncol
July 2024
Article Synopsis
- Retifanlimab, a monoclonal antibody targeting programmed death 1, is being tested for safety and effectiveness in patients with recurrent microsatellite instability-high/mismatch repair deficient endometrial cancer.
- In a study involving 76 patients, half experienced significant side effects, with anemia and fatigue being the most common, but many also achieved positive treatment responses.
- The results indicate that retifanlimab is generally well tolerated and shows promising anti-tumor activity, with some patients having a progression-free survival of over a year.
Background: Rivoceranib is an oral, selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. ANGEL (NCT03042611) was a global, randomized, double-blinded, placebo-controlled, phase 3 study evaluating rivoceranib as 3rd-line or ≥4th-line therapy in patients with advanced/metastatic gastric or gastroesophageal junction (GEJ) cancer.
Methods: Patients had failed ≥2 lines of chemotherapy and were randomized 2:1 to rivoceranib 700 mg once daily or placebo with best supportive care.
Background: Tumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA SP263 and Dako 22C3) for identification of PD-L1 patient subgroups (negative, positive, low, and high expression) and their predictive value for adjuvant atezolizumab compared with best supportive care (BSC) in resectable early-stage non-small cell lung cancer (NSCLC).
Methods: PD-L1 expression was assessed by the SP263 assay, which measured the percentage of tumor cells with any membranous PD-L1 staining, and the 22C3 assay, which scored the percentage of viable tumor cells showing partial or complete membranous PD-L1 staining.
Results: When examining the concordance at the PD-L1-positive threshold (SP263: tumor cell (TC)≥1%; 22C3: tumor proportion score (TPS)≥1%), the results were concordant between assays for 83% of the samples.
Objective: The aim: To determine the accumulation of heavy metals, namely Cr, Cd, Cu, Pb, Zn by a tumour in correlation with unaffected colon tissue and blood of patients with colorectal cancer.
Patients And Methods: Materials and methods: The study is based on the results of observation of 180 patients with CRC. The following samples were taken from: the tumor, the colon and blood unaffected by the tumor - during the operative treatment of patients in the surgical department of the communal non-profit enterprise "Precarpathian Clinical Oncology Center of the Ivano-Frankivsk regional council" for 2018-2020.
Purpose: Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial (ClinicalTrials.gov identifier: NCT03495882) evaluated the combination of balstilimab plus zalifrelimab in patients with recurrent and/or metastatic cervical cancer who relapsed after prior platinum-based therapy.
View Article and Find Full Text PDFObjective: The aim: To evaluate the early and late results of treatment of rectal cancer patients after special treatment methods with a view to indentifying optimal method of treatment in correlation with the stage of the disease.
Patients And Methods: Materials and methods: The study is based on the results of observation of 779 patients with stage II, III and IV rectal cancer (RC) who were divided into groups according to the treatment (surgery, surgery + chemotherapy, chemotherapy, surgery + chemotherapy + radiation therapy, radiation therapy + surgery, radiation therapy).
Results: Results: According to the results obtained, the overall survival of patients correlates with the stage of rectal cancer: we see the highest percentage of patients' survival in stage II and, accordingly, the lowest - in stage IV in each of the studied time intervals.
Objective: The aim: To evaluate and analyze early and late results of treatment of patients with rectal cancer after chemotherapy.
Patients And Methods: Materials and methods: The study is based on the results of observation of 779 patients with stage II, III and IV rectal cancer (RC) who were divided into groups according to the chemotherapy treatment.
Results: Results: In the course of chemotherapy treatment of RC patients, most of them received the FOLFOX regimen treatment - 87 patients (43.
Background: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.
Methods: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients).
Objective: The aim of the study is to improve the overall survival rates of patients with colon cancer, analyzing the results of chemotherapy in municipal institution «Precarpathian Clinical Oncology Center» and determining the appropriate scheme of chemotherapy in correlation with the stage of the disease.
Patients And Methods: Materials and methods: The basis of the study was the results of the observation of 973 patients with colon cancer (CC). The direct and long-term results of chemotherapy of colon cancer were studied and evaluated.